摘要
目的总结分析发生HBV YMDD变异的慢性乙型肝炎患者应用阿德福韦酯治疗2年的效果。方法选择服用拉米夫定后发生YMDD变异患者共32例为研究对象,同时服用阿德福韦酯(治疗剂量为10mg/d)和拉米夫定(治疗剂量为100mg/d)24个月。分别于治疗开始及治疗后6、12、24个月检测ALT、AST、HBeAg及HBV DNA定量,并进行对比分析。结果 HBV YMDD变异患者采用拉米夫定和阿德福韦酯联合治疗后,随着治疗疗程的延长,血清ALT、AST、及HBV DNA载量均明显下降(P均<0.05)。到治疗终点,有84.4%(27/32)的患者ALT、AST恢复正常,40.6%(13/32)的患者HBeAg转阴。结论阿德福韦酯联合拉米夫定治疗HBV YMDD变异的慢性乙型肝炎患者效果肯定。
Objective To analysis the efficacy of 2 years of adefovir dipivoxil and lamivudine in patients with chronic hepatitis B and HBV YMDD mutation after 2 years. Methods 32 patients with chronic hepatitis B and HBV YMDD mutation which happened after lamivudine treatment were selected, they were given adefovir dipivoxil（dose was 10mg/d） and lamivudine（dose was 100mg/d） for 24 months. ALT, AST, HBeAg and HBV DNA level were detected in their serum before and after drug treatment respectively. Results After adefovir dipivoxil and lamivudine treatment, the serum ALT, AST and HBV DNA level decreased in all patients（P〈0.05 for all）. At the end of treatment, 84.4% （27/32）patients＇ serum ALT and AST got normal. 40.6% （13/32） patients＇ HBeAg became negative. Conclusion The efficacy of adefovir dipivoxil and lamivudine in patients with chronic hepatitis B and HBV YMDD mutation is positive.
出处
《中国煤炭工业医学杂志》
2013年第1期7-8,共2页
Chinese Journal of Coal Industry Medicine
